IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM

免疫学和癌症免疫治疗计划(ICIP)的目标是通过学术联合 参与和协作基础和临床免疫学家的努力，以发展被动和主动 治疗癌症的免疫策略。ICIP通过将已建立的和 NCI资助的经验丰富的临床试验专家与NCI资助的癌症免疫学家和免疫学家一起 开发、设计、执行、有效监测和实现达特茅斯发起的免疫疗法试验 肾细胞癌、黑色素瘤、结肠癌、乳腺癌、胶质母细胞瘤和骨髓瘤。ICIP有18个 来自5个部门的成员和超过830万美元的总资金，其中超过250万美元 来自NCI(31%)。自2003年以来，ICIP发表了190多篇论文，其中8%涉及方案内论文 协作和13%涉及方案间协作。自2003年以来，广度 ICIP内部的免疫学专业知识的深度得到了极大的加强和集中。ICIP 专注于开发预防癌症的疫苗战略，意在推动这些 战略进入达特茅斯的临床试验。被动(T细胞过继治疗)和主动(树突状细胞) 已经开发了(DC)和基于分子的疫苗，其中一些已经进入临床试验。这个 这些试验的开发和执行极大地受益于CCSG支持的共享 资源，特别是免疫监测。促进了ICIP的重点和发展 NCCC对关键初级教员的战略招聘。反过来，他们的工作又得到了极大的便利 NCCC试点项目支持，其中一些项目得到了CCSG的支持。ICIP的专业知识现在包括 科学领域对癌症疫苗的成功开发最为重要。建立一个关键的 大量明确界定的领域的专家使ICIP的互动式“工作组”联合会成为可能 在肿瘤免疫治疗领域有明确目标的专家。ICIP成员研究自然免疫 对癌症的反应，即肿瘤生长所引起的免疫和抑制。区议会的角色 在调节肿瘤抑制以及肿瘤免疫方面，由许多实验室在 ICIP。激发对癌症的强大细胞免疫反应的分子疫苗正在研制中 是为翻译成人类而开发的。ICIP已经为现在和未来的翻译制定了愿景 癌症疫苗进入人体。

The goal of the Immunology and Cancer Immunotherapy Program (ICIP) is to unite through scholarly engagement and collaboration the efforts of basic and clinical immunologists to develop passive and active immunization strategies to treat cancer. ICIP adds value to NCCC by bringing together established and experienced NCI-funded, clinical trialists with NCI-funded cancer immunologists and immunologists to develop, design, execute, effectively monitor, and bring to fruition Dartmouth-initiated immunotherapy trials in renal cell carcinoma, melanoma, colon cancer, breast cancer, glioblastoma, and myeloma. ICIP has 18 members from 5 departments and more than $8.3 million in total funding, of which greater than $2.5 million derives from the NCI (31%). Since 2003, ICIP has published over 190 papers of which 8% involve intraprogrammatic collaborations and 13% involve inter-programmatic collaborations. Since 2003, the breadth and depth of the immunological expertise within the ICIP has been greatly strengthened and focused. ICIP has focused on the development of strategies to vaccinate against cancer, with the intent to move these strategies into clinical trials at Dartmouth. Both passive (T cell adoptive therapy) and active (dendritic cell (DC) and molecularly based) vaccines have been developed, some of which have entered clinical trials. The development and execution of these trials have greatly benefited from the CCSG-supported shared resources, especially Immune Monitoring. Enhanced ICIP focus and development has been facilitated by the strategic recruitment of key junior faculty by the NCCC. Their work, in turn, has been greatly facilitated by NCCC pilot project support, some of which was CCSG-supported. ICIP expertise now encompasses the scientific areas most important for the successful development of cancer vaccines. Establishment of a critical mass of experts in well-defined areas has enabled interactive "Working Groups"¿confederations of ICIP experts with specific goals in the area of tumor immunotherapy. ICIP members study the natural immune responses to cancer¿i.e., both the immunity and suppression elicited by a growing tumor. The role of DCs in mediating tumor suppression as well as tumor immunity is studied by a number of laboratories within the ICIP. Molecularly based vaccines to trigger robust cell-mediated immune responses to cancer are being developed for translation into humans. ICIP has formulated a vision for the present and future translation of cancer vaccines into humans.